Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Double-blind, randomized into two arms (TC and TP): patients get either topical cannabidiol
or topical placebo up to three times daily. Inclusion criteria will be chronic joint pain
with intent to treat or currently treated with opioids. Exclusion criteria will include
current cannabis use, severe medical illness or lacking in capacity to be involved in study.
TC and TP will be prescribed for use TID in predefined dosages and quantities.
Phase:
Phase 1
Details
Lead Sponsor:
Louisiana State University Health Sciences Center Shreveport